Immunization of high-risk paediatric populations: Central European Vaccination Awareness Group recommendations

Richter, Darko; Anca, Ioana; André, Francis; Bakır, Mustafa; Chlíbek, Roman; Čižman, Milan; Mangarov, Atanas; Mészner, Zsófia; Pokorn, Marko; Prymula, Roman; Salman, Nuran; Šimurka, Pavol; Tamm, Eda; Tešović, Goran; Urbancikova, Ingrid; Usonis, Vytautas; Wysocki, Jacek; Zavadska, Dace

doi:10.1586/14760584.2014.897615

Cited by 8 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recommendations from the Central European Vaccination Awareness Group, published in 2014, aim to raise awareness and formalize guidance on immunization in high-risk pediatric populations across central Europe [52].…”

Section: Vaccination Programs and Coveragementioning

confidence: 99%

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review

Mészner

Wysocki

Richter

et al. 2019

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in both individual burden and societal costs. Despite these benefits, there is no standardization of varicella immunization policies in Europe, including countries in Central and Eastern Europe (CEE). Areas covered: This systematic literature review identified publications on the epidemiology of varicella, its associated health and economic burden, and vaccination strategies within the CEE region, defined as Albania,

show abstract

Section: Vaccination Programs and Coveragementioning

confidence: 99%

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review

Mészner

Wysocki

Richter

et al. 2019

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since IPD (including meningitis) is a vaccine-preventable illness [ 2 , 12 , 13 ], vaccination against S. pneumonia in patients with cochlear implants is important and recommended universally [ 13 , 14 ]. WHO recommends the use of pneumococcal conjugate vaccines in all countries and considers their use to be a priority in all national immunization programs [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Currently, there are two types of pneumococcal vaccines on the market: a 23-valent polysaccharide vaccine (PPV23) and three conjugate vaccines: 7-valent (PCV7), 10-valent (PCV10), and 13-valent (PCV13) [ 2 ]. However, the availability of vaccines, and national immunization programs or vaccination strategies, varies between European countries [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Rates of Vaccination against Streptococcus Pneumoniae in Cochlear Implant Patients

Piotrowska

Paradowska-Stankiewicz

Skarżyńśki

2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundStreptococcus pneumoniae can cause life-threatening illness, with invasive pneumococcal diseases (IPD) like meningitis, sepsis, bacteremic pneumonia, and bacteremia being major causes of morbidity and mortality. Studies have shown that patients who have had a cochlear implant, particularly children, have an increased risk of bacterial (pneumococcal) meningitis. Vaccination in patients with cochlear implants is important and recommended universally. The World Health Organization recommends the use of pneumococcal conjugate vaccines in all countries and considers their use to be a priority in all national immunization programs. The objective of this study was to assess rates of vaccination against Streptococcus pneumoniae in patients with cochlear implants who were implanted at the Institute of Physiology and Pathology of Hearing, Poland.Material/MethodsWe analyzed data from questionnaires administered to 2,628 patients who visited the Implants and Auditory Perception Department (IAPD) of the Institute of Physiology and Pathology of Hearing between January 2014 and March 2016.ResultsThe percentage of vaccinated patients in the study group was 28.2%, most of whom (90.7%) were children. Among the children, 49.3% were vaccinated against S. pneumoniae, but the corresponding rate for adults was only 5.5%.ConclusionsThe percentage of patients with cochlear implants who received vaccination against S. pneumoniae was low, both in children and adults, but especially in adults comparing to available reports.

show abstract

“…It has been a long-term issue for children with uncontrolled epilepsy and progressive neurological diseases may not be adequately vaccinated. 24 The main concern among this special group is that the vaccine may trigger the recurrence of seizure. 25 A multicentred healthy-control prospective study of adults in China found no evidence suggesting worsening seizures after inactivated COVID-19 vaccination in adults.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccine counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study

Zeng

Zhai

Chang

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Safety concerns about novel vaccines and necessity of COVID-19 vaccination for children, especially with underlying medical conditions, are the obstacle of COVID-19 vaccination program among pediatric population. The study was conducted to investigate the vaccine hesitancy reasons among the parents, and to monitor the adverse events of inactivated COVID-19 vaccines in children and teenagers with underlying medical conditions in China. Children with underlying medical conditions encountered to the Immunization Advisory Clinic for COVID-19 vaccine counseling were enrolled. They were given immunization recommendation and followed up at 72 h and 28 d after immunization to monitor the immunization compliance after consultation and adverse events. A total of 324 children aged 3–17 y were included. The top three primary medical conditions for counseling were allergy (33.6%), neurological diseases (31.2%) and rheumatic diseases (8.3%). COVID-19 vaccination was promptly recommended for 242 (74.7%) children. Seventy-one (65.7%) children who had allergy issues were recommend to take vaccination, which was significantly lower than that of other medical conditions ( p < .05). The follow-up record showed that 180 children received 340 doses of inactivated COVID-19 vaccine after consultation. Overall, 39 (21.6%) children reported at least one adverse event within 28 d of either vaccination. No serious adverse reactions were observed. No difference of adverse effects between the first dose and the second dose of vaccination except fever. Parents’ hesitancy in COVID-19 vaccination for children with underling medical conditions are mainly due to the safety concerns. Specialist consultation is helpful to improve the vaccine uptake.

show abstract

Immunization of high-risk paediatric populations: Central European Vaccination Awareness Group recommendations

Cited by 8 publications

References 54 publications

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review

Rates of Vaccination against Streptococcus Pneumoniae in Cochlear Implant Patients

COVID-19 vaccine counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study

Contact Info

Product

Resources

About